KEY POINTS
- Recce raised A$4 million from institutions at A$0.40 a share and opened a share purchase plan to raise up to A$4 million more, for a target of up to A$8 million.
- Despite the cash and a Middle East licensing plan, the shares fell about 13% (after falling nearly 20% during the day) because the placement was priced below the market and diluted existing holders.
- The science is real (synthetic drugs aimed at antibiotic-resistant superbugs), but Recce is still pre-revenue and raises money often.
- Our view: a promising pipeline, but the dilution risk stays until real sales arrive.
Recce Pharmaceuticals (ASX:RCE) gave investors what looked like good news: fresh funding and a push to sell its lead drug in the Middle East. Yet the shares fell about 13% to close at A$0.40, after dropping as low as A$0.37 early in the day. It seems odd that money in the bank and a new market plan would send a stock down. But for early-stage biotech investors, the reason is familiar, and it comes down to one word: dilution.
Why the Market Sold the News
The raise was priced at A$0.40 per share, a discount to where Recce had been trading. The company brought in A$4 million from institutions and opened a share purchase plan to raise up to A$4 million more, aiming for up to A$8 million in total.
Here is the catch. When a company sells new shares below the market price, it creates more shares, so each existing share is worth a little less. That may sound technical, but it simply means today’s owners get a smaller slice of the pie. Cheaply priced raises almost always drag the share price down towards the offer price. That is exactly what happened here: Recce fell below the A$0.40 placement price to as low as A$0.37 before closing right at that A$0.40 level.
The Middle East deal adds to the caution. It is a non-binding term sheet, not a signed contract, so there is no guarantee it will proceed. And the key data from Recce’s Indonesian trial is still to come. In short, the market is pricing in the certainty of dilution today against benefits that remain uncertain.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
The Superbug Opportunity Behind the Raise
The bull case is genuine. Recce is developing a new class of synthetic anti-infectives designed to fight antibiotic-resistant infections, often called superbugs. This is one of the biggest unmet problems in global medicine, as more infections stop responding to existing antibiotics.
Its pipeline covers three candidates: RECCE 327 (an intravenous and topical treatment for serious bacterial infections), RECCE 435 (an oral antibiotic) and RECCE 529 (an antiviral). The near-term prize is the topical gel for diabetic foot infections, the focus of both the Middle East deal and a Phase 3 trial running in Indonesia. A strong result there could open the door to real sales, which is what the company needs most. The science is promising, but it still has to clear that final clinical and regulatory hurdle.
The Investor’s Takeaway: Promise vs Dilution
The opportunity is large, and the catalysts are clear: the Indonesian trial readout and turning the Middle East term sheet into a binding deal. But there is a recurring red flag. Recce is still pre-revenue and has raised money many times. Until real sales arrive, more raises and more dilution are likely.
For risk-tolerant investors who believe in the science, the recent fall may look like a cheaper entry into a long-term story. For more cautious investors, it may be wiser to wait for the Indonesian data and a signed Middle East deal before stepping in. Watch those two milestones closely, because they will decide which way this story turns.
